Glucagon increases blood glucose by stimulating glycogen breakdown in the liver.
Title: Glucagon increases blood glucose by stimulating glycogen breakdown in the liver. Abstract: Glucagon, a 29-amino acid peptide hormone, directly elevates blood glucose via hepatic glycogenolysis, a mechanism critical in hypoglycemia management. Market data (Grand View Research, 2023) projects the global peptide therapeutics market at $48.5 billion by 2028, with glucagon analogs driving emergency care demand. Compared to insulin, glucagon offers rapid onset (5–15 min) but shorter half-life (3–6 min). Key brands (GlucaGen, Baqsimi) differ in delivery: injectable vs. intranasal. Regulatory compliance (FDA, EMA) and cold-chain logistics (2–8°C) are essential for potency. Selection criteria prioritize purity (>98% HPLC) and stability. Industry trends favor non-invasive formulations, expanding glucagon’s role beyond rescue to metabolic disorders.